FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer

Web

Nov. 12, 2019

SCIENTIFIC

Retrospective clinical data supported by preclinical modelling suggests that FGFR1 amplification is a marker of resistance to endocrine therapy in ER+ disease; sensitivity to MTOR inhibition (eg everolimus) is maintained.

https://clincancerres.aacrjournals.org/content/25/21/6443.long